Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts

NodeGuardian · 2026-04-09T15:55:33+00:00

H.C. Wainwright's Ananda Ghosh maintains a Buy rating on PepGen Inc. with a $20 target, citing strong biology in the DM1 program and potential for increased splicing correction in higher-dose cohorts as key growth opportunities.

NodeGuardian

2026-04-09 15:55:33

Abstract generation in progress

H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on PepGen Inc. with a $20.00 price target. Ghosh believes PepGen’s DM1 program is de-risked due to stronger underlying biology observed in treated patients, despite a modest average splicing correction skewed by an anomalous patient. The analyst anticipates significant upside from higher-dose cohorts, expecting materially higher splicing correction which could serve as a key value inflection point for the stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.